John Miller

Russian billionaire wants Switzerland's Meyer Burger to raise cash, renew board

07 Dec 2018

ZURICH, Dec 6 Meyer Burger's largest shareholder on Thursday called for the money-losing Swiss solar machinery maker to renew its board of directors and to consider raising money to finance its own efforts to manufacture solar cells.

New Swiss cabinet member says EU treaty hinges on wage protections

05 Dec 2018

ZURICH A newly-elected Swiss cabinet member vowed to fight to preserve wage protections in any new treaty with the European Union, potentially complicating talks with the bloc that are already stalled over the issue.

UPDATE 1-New Swiss cabinet member says EU treaty hinges on wage protections

05 Dec 2018

* Impasse escalated in recent weeks over bourse rules (Adds comment from new cabinet member)

Swiss cabinet reshuffle could complicate talks over EU ties

05 Dec 2018

ZURICH, Dec 5 Switzerland's parliament elected to the cabinet on Wednesday two members whose apparent position on a draft pact with the European Union could complicate stalled talks with the bloc.

Roche's Tecentriq wins speedy U.S. FDA review for small cell lung cancer

05 Dec 2018

ZURICH Swiss group Roche Holding AG said on Wednesday its Tecentriq immunotherapy mixed with chemotherapy won priority review from the U.S. regulator for treating a type of lung cancer, a potential boost to the drug that has been trailing rivals' revenues.

Swiss cabinet opposes move to curb EU immigration in referendum

01 Dec 2018

ZURICH The Swiss government said on Friday it opposed curbing immigration from the European Union as proposed in a planned referendum because a yes vote could harm exports to the country's biggest trade partner.

Novartis's Alcon sees myopia epidemic driving sales growth

27 Nov 2018

ZURICH Novartis eyecare unit Alcon is counting on a nearsightedness epidemic to help to drive growth and profitability as a growing number of people damage their eyes by spending less time outdoors and more on mobile devices.

CORRECTED-UPDATE 1-Alcon sees 2020 dividend, bolt-on purchases in life after Novartis

27 Nov 2018

ZURICH, Nov 27 Novartis eye care unit Alcon, being spun off to investors next year, aims to pay a dividend from 2020 and will focus on "bolt-on" acquisitions to help boost core operating margins to the mid-20 percent range by 2023 from the high teens now.

U.S. benefits manager baulks after Novartis values gene therapy at $4-5 million

23 Nov 2018

ZURICH Just weeks after Novartis floated the idea that $4-5 million was fair value for its new gene therapy against a deadly neuromuscular disease, a major benefits manager is pushing back.

Novartis's pricing might be tested with costly eye therapy

23 Nov 2018

ZURICH Novartis's price-setting muscle is about to be tested after it won European Union approval for a blindness-fighting gene therapy whose $850,000 list cost in the United States has been labeled too expensive by some groups.

World News